ReVision Implant announced today that it received FDA breakthrough device designation for its Occular visual cortical prosthesis.

ReVision now anticipates initiating early-stage human clinical trials of its Occular BCI in blind volunteers in 2027.

About 30 million people around the world have grown legally blind due to retinal diseases. The EPI-RET project has sought for a technical solution for the past twelve years to help these patients.

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

The Intracortical Visual Prosthesis (ICVP), an implant that bypasses the retina and optic nerves to connect directly to the brain's visual cortex, has been successfully surgically implanted in the ...

There are a few notable tech inventions that have changed the medical industry forever. From the use of AI for disease detection to 3D printing biomedical implants and drugs, advances in modern ...

Neural computation scientists have created a software system that is hoped to improve the function of retinal implants significantly: With the aid of the software, the visual prosthesis "learns" to ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Retinitis pigmentosa and age-related macular degeneration are two significant causes of severe visual dysfunction. In both, the retinal photoreceptors degenerate, preventing successful conversion of ...

The public markets have proven a rocky path for Second Sight Medical Products ($EYES) since strong initial investor enthusiasm peaked just after its November IPO. But ...